MRI May Improve Prostate Cancer Monitoring
Volume tracking and longitudinal imaging may enhance assessment of progression during active surveillance.
By
Kathryn Wighton
April 13, 2026
Clinical Scorecard: MRI May Improve Prostate Cancer Monitoring
At a Glance
Category Detail
Condition Prostate Cancer Key Mechanisms MRI is more accurate than PSA testing or biopsy for assessing structural changes in tumors and detecting higher-grade disease. Target Population Patients undergoing active surveillance for prostate cancer. Care Setting Clinical settings utilizing active surveillance protocols.
Key Highlights
MRI should emphasize change over time rather than single time points. Volume assessment may better reflect tumor burden than maximum diameter. The PRECISE system provides a standardized framework for reporting changes. Longitudinal assessment improves clinical interpretation of MRI findings. Changes in tumor volume and growth rates are critical for monitoring progression. Guideline-Based Recommendations
Diagnosis
Use MRI for monitoring structural changes in prostate cancer. Management
Integrate MRI findings with clinical factors like PSA levels and patient characteristics. Monitoring & Follow-up
Focus on measurable changes over time, such as tumor volume and growth rates. Risks
Consider patient age, comorbidities, and prior histologic findings when determining the need for repeat biopsy or treatment. Patient & Prescribing Data
Patients on active surveillance for prostate cancer.
MRI should be used serially to assess changes in tumor characteristics.
Clinical Best Practices
Review prior MRI studies together for comprehensive assessment. Measure lesion volume consistently at each time point. Combine qualitative and quantitative data in reporting. Related Resources & Content
